AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents

AI justification

The deal fails to address patent barriers to HIV prevention drug access, violating rights to health and equality. | The R&D pact between the U.S. government and Gilead includes positive research provisions, but activists argue it fails to address critical access barriers, violating rights to health and equality.